At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 18 enrolled
Drug / intervention
Utomilumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1B Dose Escalation Trial of Human Anti 4 1BB Agonistic Antibody Utomilumab (PF 05082566) in Combination With Ado Trastuzumab Emtansine or Trastuzumab in Patients With HER2 Postive Advanced Breast Cancer
In Brief
A Phase 1 clinical trial evaluating Utomilumab, Trastuzumab, and 1 other intervention for HER2 Positive Breast Carcinoma and 6 related conditions. Completed, enrolled 18 participants across 1 site.
Detailed Summary
This trial studies the best dose and side effects of utomilumab (4-1BB agonist monoclonal antibody PF-05082566) with trastuzumab emtansine or trastuzumab in treating patients with HER2-positive breast cancer that has spread to other places in the body. Monoclonal antibodies, such as utomilumab, trastuzumab emtansine, and trastuzumab may interfere with the ability of tumor cells to grow and spread.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
Enrollment StartOct 2017
First PostedDec 2017
Primary CompletionFeb 2021
Study CompletionFeb 2022
TodayJul 2026
First PostedDec 6, 2017
Enrollment StartOct 30, 2017
Primary CompletionFeb 15, 2021
Study CompletionFeb 14, 2022
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 8.6 years ago
Interventions
Utomilumabdrug
Given IV
Trastuzumabdrug
Given IV
Ado-Trastuzumab Emtansinedrug
Given IV